electroCore Aims Noninvasive Neurostimulation At The Masses
This article was originally published in Start Up
Armed with a $40 million Series A financing, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. With drug firms upping their interest in so-called “electroceuticals,” it could signal a shift away from certain pharmaceutical treatments.
You may also be interested in...
Electroceuticals: Drug-Like Effects, Without The Drugs
Electroceuticals could replace the use of pharmaceuticals in many chronic diseases, offering effective treatments without, perhaps, side effects. Medtechs pioneering these next-gen neuromodulation devices are sparking investor interest.
Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
Deals Of The Week Looks At Pricing Conundrums
New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.